Fig. 2

Difference in the proportion of patients achieving a 75% importance in the Psoriasis area and severity index (PASI75) between treatment and placebo for (A) All includes studies (B) Studies with tofacitinib as experimental group and (C) Studies with non- tofacitinib JAK inhitors as experimental group